

CyGenics Ltd (ACN 108 051 529)

Australia • Level 4 • 414 Lonsdale Street • Melbourne • Victoria 3000 • Australia

Phone 1800 333 050 • Facsimile (61) 03 9445 9224

Singapore • 600 North Bridge Road • Parkview Square • #12-09/10 • Singapore 188776

Phone (65) 6238 0808 • Facsimile (65) 6295 1108 • www.cygenics.com



Monday 26 July 2004

NATIONAL INSTITUTES OF HEALTH RENEWS US\$272,000 CYGENICS CONTRACT

Contract for T-cell technology renewed for second year

Listed stem cell biotechnology company, CyGenics Limited (ASX:CYN), today announced its contract with the US National Institutes of Health (NIH) worth US\$272,000 has been renewed for a second year.

The contract for CyGenics' T-cell technology was secured via its Boston-based Cytomatrix business unit and is scheduled to run until June 2005.

The contract, entitled *Immune Reconstitution by Thymic Organoid in Murine BMT*, will conduct tests to further develop the company's T-cell technology to reconstitute the immune system in mice. This seeks to provide *in vivo* animal data about the ability of the T-cells produced in the company's *ex vivo* artificial thymus to engraft back into the mouse immune system. The technology could eventually be used to help cancer patients recover immune systems that have been severely damaged by chemotherapy, radiotherapy or disease.

The NIH is part of the US Department of Health and Human Services and the primary federal agency for conducting and supporting medical research in the US. The NIH leads the way in changing people's health through investigating ways to prevent diseases as well as the causes, treatments, and cures of common and rare diseases.

"We enjoy a long and valued relationship with the NIH," said Dr Michael Rosenzweig, Chief Scientific Officer of CyGenics.

"This contract serves to further validate the capabilities of our artificial thymus. This contract also marks the last of our pre-clinical work on this technology as we prepare to begin our Phase I/II clinical trials later this year."

Dr Mark Pykett, President, CyGenics, said that in its current pre-clinical stage, the artificial thymus is already generating revenue, such as in the field of vaccine screening.



“The intention of the artificial thymus is ultimately to deliver a simple, cost-effective and patient-specific ability to generate new human T-cells. By making new, fully functional T-cells, the company would be able to provide a platform with the potential for producing applications to treat a wide array of diseases, to the benefit of millions of patients around the world.”

++Ends++

About CyGenics

CyGenics is a biotechnology company focused on the development and commercialisation of stem cell-related products, services, applications and technologies. From its headquarters in Australia, CyGenics operates three divisions: Singapore-based CordLife (tissue banking services, in particular, cord blood banking) and Cell Sciences (consumable cell culture products), and Cytomatrix (cell therapeutics and technology development) based in the USA. CyGenics is listed on the Australian Stock Exchange, under the symbol CYN. For more information, please visit www.cygenics.com.

For more information, please contact:

Ronald Hee
Corporate Communications &
Marketing Manager
CordLife Pte Ltd
600 North Bridge Road,
#12-09/10, Parkview Square,
Singapore 188778
Singapore
Tel : +65 6238 0808
Fax : +65 6295 1108
Mobile: +65 9061 9098
Email: rhee@cordlife.com

Gail McIsaac
Senior Consultant, Healthcare
Fleishman-Hillard Pte Ltd
50 Raffles Place
#24-06 Singapore Land Tower
Singapore 048623
Singapore
Tel: +65 6339 1066
DID: +65 6424 6370
Fax: +65 6424 6355
E-mail: mcisaacg@fleishman.com

Rod Nockles
Director
Financial & Corporate Relations
Level 20,
114 William Street
Melbourne Victoria 3000
Australia
Tel: +61 3 9670 7996
Fax: +61 3 9670 3883
Mobile: +61 (0) 419 691 323
E-mail: r.nockles@fcr.com.au

